PROCEPT BioRobotics (NASDAQ:PRCT) mentioned it has obtained FDA approval to conduct a research investigating the protection and efficacy of Aquablation remedy within the remedy of prostate most cancers.
PROCEPT mentioned the research’s findings can be used to help future analysis and US regulatory functions. The one-arm feasibility research will enroll sufferers with localized prostate most cancers at three testing websites within the US.
Aquablation is already used to deal with benign prostatic hyperplasia. The remedy, which is delivered utilizing PROCEPT’s Aquabeam Robotics system, makes use of high-pressure water for the focused removing of prostate tissue.